IN8bio presents GBM trial data: mPFS 13.0 mo vs 6.6 SOC; mOS not reached at 16.4+ mo

IN8BIO, INC.

Phase 1 INB-200 and Phase 2 INB-400 data presented at SNO 2025 for newly diagnosed glioblastoma.
14 patients received repeated DeltEx DRI gamma-delta T cells; mPFS 13.0 months vs 6.6 for SOC (n=10).
Median OS not yet reached for DRI patients at 16.4+ months as of Oct 31, 2025; SOC mOS 11.0 months.
17 patients treated across both trials; 10 additional SOC-only patients monitored for comparison.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.